Copay Programs, Coupons And Other Risky MC Maneuvers
12-10-2026 03:28 via pharmacypracticenews.com

Copay Programs, Coupons And Other Risky MC Maneuvers

Originally published by our sister publication Specialty Pharmacy ContinuumBy Gina ShawAs pharmacy benefit managers (PBMs) expand the use of copay accumulators, copay maximizers, alternative funding programs (AFPs), and prescription discount cards, specialty pharmacies are finding themselves caught in benefit designs that shift financial risk while obscuring who ultimately controls access to therapy.These programs are drawing heightened scrutiny as specialty drug spending continues to rise, manu
Read more »

Pharmacy news



Combination bnAbs Sustained Viral Suppression in Children After ART Interruption
Combination bnAbs Sustained Viral Suppression in Children After ART Interruption
Brief Caregiver Education Boosts TD Evaluation and Diagnosis
Brief Caregiver Education Boosts TD Evaluation and Diagnosis
FDA Approves Extended-Release Form of Olanzapine for Treatment of Schizophrenia
FDA Approves Extended-Release Form of Olanzapine for Treatment of Schizophrenia
FDA Approves Remibrutinib for Treatment-Resistant Symptomatic Dermographism
FDA Approves Remibrutinib for Treatment-Resistant Symptomatic Dermographism
Registry Data Support Treating Mild Tardive Dyskinesia
Registry Data Support Treating Mild Tardive Dyskinesia
Pharmacy-Led Revenue Cycle Work Closes Billing Gaps, Speeds Treatment
Pharmacy-Led Revenue Cycle Work Closes Billing Gaps, Speeds Treatment
In-House Pharmacy Benefit Flattens Costs, Keeps Employees on GLP-1s
In-House Pharmacy Benefit Flattens Costs, Keeps Employees on GLP-1s
Deutetrabenazine Response Can Emerge After 15 Weeks, Post Hoc Analysis Suggests
Deutetrabenazine Response Can Emerge After 15 Weeks, Post Hoc Analysis Suggests
FDA Approves Degevma, Biosimilar to Xgeva
FDA Approves Degevma, Biosimilar to Xgeva
Financial Success Hinges on Proactive Enterprise Planning
Financial Success Hinges on Proactive Enterprise Planning
AAM Report: Generics and Biosimilars Saved $496 Billion in 2025
AAM Report: Generics and Biosimilars Saved $496 Billion in 2025
Innovative Oral Anticancer Therapy Monitoring In Health-System Specialty Pharmacy
Innovative Oral Anticancer Therapy Monitoring In Health-System Specialty Pharmacy
Closing the Rx Gap Between Oncology Guidelines and Practice
Closing the Rx Gap Between Oncology Guidelines and Practice
The Ongoing Struggle of Sickle Cell Disease
The Ongoing Struggle of Sickle Cell Disease
Desktop versie